

# CONCEPT NOTE

---

## **How to strengthen the Health Expertise in the EU ?**

### **The conditions for a fair, efficient et reliable expertise ?**

---

#### Themes

- **Building, Managing, Financing and Evaluating the expertise**
  - **DG SANCO, EMA and ECDC Procedures**
  - **Conflict of interests**
  - **Best practices**
  - **Insights from NGO and Corporate stakeholders**
- 

**26 Octobre 2010, 10:00 – 12:00**

Room A5E1, European Parliament, Brussels

#### **Hosts**

**Michele Rivasi MEP, The Greens/EFA**

**Corinne Lepage MEP, ALDE**

**An Expert Workshop of the Own Initiative Report on the Evaluation of the management of H1N1 influenza in 2009-2010 in the EU**

---

#### **Event summary**

The management of H1N1 influenza in the European Union induced a deep confidence crisis of the European citizens to our health institutions. Expertise has been particularly under fire especially critical evaluation of real or potential risk and the proposed recommendations.

A critical analysis strengthened by an efficient expertise is needed for the Commission to be well informed and able to take decisions in a timely schedule. The European health institutions statements on the H1N1 crisis demonstrate that the rules of expertise have to be modify. This assessment is mainly relevant for the European Medicines Agency whose operational expertise mainly depends on four member states expertise.

That workshop about expertise is organized under the rule of the parliamentary report on the Evaluation of the management of H1N1 influenza in 2009-2010 in the E.U. By associating European agencies and stakeholders from industry and NGO, it is aimed at building conditions for a fair, efficient and reliable expertise.

# CONCEPT NOTE

---

## PRELIMINARY PROGRAM

10.00: Welcome : *Corinne Lepage MEP*

10.05: Keynote : Pourquoi cet atelier // H1N1 Ini report ? : *Michele Rivasi MEP*

---

### 10:10: DISCUSSION ONE - THE CONDITIONS "TO BE" AN EXPERT ?

***Moderator: Corinne Lepage MEP***

How to recruit the experts ? What criterias of selection ? Which relationship with pharmaceutical industries ?

*Participants : DG SANCO, EMA, ECDC, Marc Girard, Philip Carter*

10.40: Questions and answers

---

### 11:05: DISCUSSION TWO - THE CONDITIONS "TO MAKE" EXPERTISE ?

***Moderator: Michele Rivasi MEP***

What are the object and/or the limits of the expertise ? What kind of resulting datas are needed ? Which expertise methodology ? Which transparency ? Which internal control and external watchdogs ?

*Participants : DG SANCO, EMA, ECDC, Marc Girard, Philip Carter....*

11:30: Questions and answers

11:50: Lessons for a better Health Expertise in the EU : *Corinne Lepage MEP*

11:55: Conclusion & H1N1 Follow-up : *Michele Rivasi MEP*

---

## PARTICIPANTS

DG SANCO : John F. Ryan, Head of Unit (Health Threats Unit)

DG SANCO : Dr Robert Vanhoorde. Head of Unit (Science and Stakeholder Relations)

ECDC : Dr Marc Sprenger, Director of the ECDC

EMA : Dr Patrick Le Courtois, Head of Unit (Human Medicines Development and Evaluation)

EMA : Dr Noel Wathion, Head of Unit (Patient Health Protection)

Dr Marc Girard, French Expert on Pharmacovigilance, Author of "Alertes grippales" (2009)

Philip Carter (UK), Bureau of Investigative Journalism, on the Tamiflu evaluation case (tbc)

# CONCEPT NOTE